|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Trans-ethnic association study of blood pressure determinants in over 750,000 individuals.
|
30578418 |
2019 |
|
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals.
|
27618452 |
2016 |
|
Blood Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure.
|
21909110 |
2011 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Since altered expression of protein kinase B (PKB)/Akt in breast cancer cells affect N-myristoyltransferase 1 (NMT1) expression and activity, we investigated whether mTOR, a downstream target of PKB/Akt, regulates NMT1 in ER positive breast cancer cells (MCF7 cells).
|
30154572 |
2018 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
These studies provide a preclinical proof of concept for targeting NMT1 as a strategy to treat breast cancer.
|
30446635 |
2018 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Since altered expression of protein kinase B (PKB)/Akt in breast cancer cells affect N-myristoyltransferase 1 (NMT1) expression and activity, we investigated whether mTOR, a downstream target of PKB/Akt, regulates NMT1 in ER positive breast cancer cells (MCF7 cells).
|
30154572 |
2018 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These studies provide a preclinical proof of concept for targeting NMT1 as a strategy to treat breast cancer.
|
30446635 |
2018 |
|
Amelogenesis imperfecta nephrocalcinosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrated that diabetic rats exhibited a decrease in the mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL), and that NMT is increased and TWL is prolonged in rats treated with tanshinone II A. Additionally, the levels of ERS-signaling pathway factors in the spinal dorsal horns of rats were lower in the tanshinone IIA-treated group than in the diabetic group.
|
31295750 |
2020 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that RA T cells had a defect in NMT1 function, which prevented AMPK activation and enabled unopposed mTORC1 signaling.
|
30718913 |
2019 |
|
melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Tris(dibenzylideneacetone)dipalladium (Tris DBA-Pd) is a novel inhibitor of N-myristoyltransferase 1 (NMT-1) and has proven in vivo activity against melanoma.
|
30824801 |
2019 |
|
nervous system disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
We performed a comprehensive analysis of the Doctors' Trials original documents (NMT 1: Medical Case) as well as other available academic and historical sources focusing on references to the nervous system, neurosurgical, and neurologic diseases.
|
30368013 |
2019 |
|
Synovitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In vivo, NMT1 loss caused robust synovial tissue inflammation, whereas forced NMT1 overexpression rescued AMPK activation and suppressed synovitis.
|
30718913 |
2019 |
|
Depressive Symptoms
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Group differences in depressive symptoms between the MT and NMT adolescents were partly accounted by differences in sgACC-FPN RSFC.
|
30196872 |
2018 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In this study, we demonstrated that genetic inhibition of N-myristoyltransferase NMT1 suppressed initiation, proliferation and invasion of breast cancer cells either in vitro or in vivo.
|
30446635 |
2018 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we provide genetic and pharmacologic evidence that inhibiting the <i>N</i>-myristoyltransferase NMT1 suppresses cell-cycle progression, proliferation, and malignant growth of prostate cancer cells.
|
29038344 |
2017 |
|
Lymphadenitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report the first case of NMT lymphadenitis in a child caused by Mycobacterium marseillense, a newly described species belonging to Mycobacterium avium complex.
|
29017528 |
2017 |
|
Mycobacterium avium-intracellulare Infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report the first case of NMT lymphadenitis in a child caused by Mycobacterium marseillense, a newly described species belonging to Mycobacterium avium complex.
|
29017528 |
2017 |
|
Squamous cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Elevated N-myristoyltransferase activity and expression in oral squamous cell carcinoma.
|
17549352 |
2007 |
|
Colonic Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
N-myristoyltransferase: a potential novel diagnostic marker for colon cancer.
|
18021392 |
2007 |
|
Brain Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Based on our previous findings of elevated N-myristoyltransferase (NMT) activity in colonic epithelial neoplasms that appears at an early stage in colonic carcinogenesis, together with elevated NMT expression in human colorectal and gallbladder carcinomas, we investigated NMT activity and protein expression of NMT1 and NMT2 in human brain tumors and documented elevated NMT activity and higher protein expressions.
|
15756927 |
2005 |
|
Infection
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Novel strategy for anti-HIV-1 action: selective cytotoxic effect of N-myristoyltransferase inhibitor on HIV-1-infected cells.
|
12220649 |
2002 |